Janux Therapeutics
Latest round
- Series B
Last raised
- Apr 2021
Total raised
- $181M
Investors
- 12
About Janux Therapeutics
Founded in 2017 and based in California, US, Janux Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies for cancers. The company was founded by President and CEO David Campbell.50 per share, on the Nasdaq Global Select Market under the ticker symbol "JANX". Janux Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of common stock as part of the listing. In December 2024, Janux Therapeutics, Inc.31 million shares at USD 63 per share, on the Nasdaq Global Select Market under the ticker symbol "JANX". Janux Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock as part of the listing. Janux Therapeutics is a biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology that treats patients suffering from cancer. Janux Therapeutics focuses on developing a novel class of T cell engagers (TCEs), and its product candidates designed to target clinically validated drug targets. The company's TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developed to treat solid tumors and faced challenges due to the limitations of prior technologies, namely (I) overactivation of the immune system leading to cytokine release syndrome, (II) on-target, healthy tissue toxicities, and (III) poor pharmacokinetics leading to short half-life. Janux is also developing pipelines with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). The company plans to support the advancement of its pipeline T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.
Who invested in Janux Therapeutics
12 investors across 2 rounds
See all investors in Janux Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Janux Therapeutics
Who invested in Janux Therapeutics?
Janux Therapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Janux Therapeutics raised?
Janux Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Janux Therapeutics last raise money?
Janux Therapeutics's most recent round on record is a Series B, in Apr 2021.
What does Janux Therapeutics do?
Founded in 2017 and based in California, US, Janux Therapeutics, Inc.
Where is Janux Therapeutics headquartered?
Janux Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Janux Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Janux Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Janux Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.